Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2015

01.12.2015 | Hepatobiliary Tumors

Adjuvant Chemotherapy and Radiation Therapy is Associated with Improved Survival for Patients with Extrahepatic Cholangiocarcinoma

verfasst von: Richard S. Hoehn, MD, Koffi Wima, MS, Audrey E. Ertel, MD, Alexandra Meier, BS, Syed A. Ahmad, MD, Shimul A. Shah, MD, MHCM, Daniel E. Abbott, MD

Erschienen in: Annals of Surgical Oncology | Sonderheft 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to analyze adjuvant therapy among patients with extrahepatic cholangiocarcinoma (EHC) at a national level.

Methods

The American College of Surgeons National Cancer Data Base was used to identify patients with resected EHC (pathologic stages 1–3) between 1998 and 2006 (n = 8741). Three groups were compared: surgery only (S, n = 5766), surgery plus adjuvant chemotherapy (AC, n = 450), and surgery plus adjuvant chemotherapy and radiation therapy (ACR, n = 1918). The study investigated how patient demographics, provider characteristics, and tumor-specific variables were associated with receipt of adjuvant therapy and overall survival.

Results

Patients who received adjuvant treatment were more likely to be younger (median age S, 70 years; AC, 65 years; ACR, 63 years), in the highest income quartile (>$46,000: S, 38.3 %; AC, 43.4 %; ACR, 44.7 %), and treated at a community cancer center (S, 43.0 %; AC, 50.7 %; ACR, 52.9 %) (all p < 0.001). These patients also were more likely to have positive lymph nodes (S, 34.7 %; AC, 69.6 %; ACR, 63.3 %), positive surgical margins (S, 5.9 %; AC, 7.1 %; ACR, 10.7 %), and stage 3 disease (S, 21.4 %; AC, 37.8 %; ACR, 37.9 %) (all p < 0.001). Multivariate analysis of the entire cohort showed improved survival with ACR (hazard ratio [HR] 0.82; 95 % confidence interval [CI] 0.75–0.91). The survival benefit was independent of margin status (R0: HR 0.88; 95 % CI 0.79–0.97; R1: HR 0.49; 95 % CI 0.38–0.62).

Conclusions

This national analysis suggests that ACR are associated with improved survival for high-risk EHC patients, such as those with positive lymph nodes. Until randomized clinical trials are conducted, these may be the best available data to guide adjuvant therapy for resected EHC.
Literatur
1.
Zurück zum Zitat Mattiucci GC, Autorino R, D’Agostino GR, et al. Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. Crit Rev Oncol Hematol. 2014;90:58–67.PubMedCrossRef Mattiucci GC, Autorino R, D’Agostino GR, et al. Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. Crit Rev Oncol Hematol. 2014;90:58–67.PubMedCrossRef
2.
Zurück zum Zitat Klempnauer J, Ridder GJ, Werner M, et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer. 1997;79:26–34.PubMedCrossRef Klempnauer J, Ridder GJ, Werner M, et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer. 1997;79:26–34.PubMedCrossRef
3.
Zurück zum Zitat Lillemoe KD. Current status of surgery for Klatskin tumors. Curr Opin Gen Surg. 1994:161–7. Lillemoe KD. Current status of surgery for Klatskin tumors. Curr Opin Gen Surg. 1994:161–7.
4.
Zurück zum Zitat Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996;223:384–94.PubMedPubMedCentralCrossRef Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996;223:384–94.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–73; discussion 473–5.PubMedPubMedCentralCrossRef Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–73; discussion 473–5.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17; discussion 517–9.PubMedPubMedCentralCrossRef Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507–17; discussion 517–9.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Murakami Y, Uemura K, Sudo T, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg. 2013;17:1429–39.PubMedCrossRef Murakami Y, Uemura K, Sudo T, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg. 2013;17:1429–39.PubMedCrossRef
8.
Zurück zum Zitat van der Gaag NA, Kloek JJ, de Bakker JK, et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642–9.PubMedCrossRef van der Gaag NA, Kloek JJ, de Bakker JK, et al. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642–9.PubMedCrossRef
9.
Zurück zum Zitat Vern-Gross TZ, Shivnani AT, Chen K, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2011;81:189–98.PubMedCrossRef Vern-Gross TZ, Shivnani AT, Chen K, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2011;81:189–98.PubMedCrossRef
10.
Zurück zum Zitat Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg. 1995;221:788–97; discussion 797–8.PubMedPubMedCentralCrossRef Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg. 1995;221:788–97; discussion 797–8.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990;159:91–7; discussion 97–8.PubMedCrossRef Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg. 1990;159:91–7; discussion 97–8.PubMedCrossRef
12.
Zurück zum Zitat Moureau-Zabotto L, Turrini O, Resbeut M, et al. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer. 2013;13:568.PubMedPubMedCentralCrossRef Moureau-Zabotto L, Turrini O, Resbeut M, et al. Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma. BMC Cancer. 2013;13:568.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Heron DE, Stein DE, Eschelman DJ, et al. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol. 2003;26:422–8.PubMed Heron DE, Stein DE, Eschelman DJ, et al. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol. 2003;26:422–8.PubMed
14.
Zurück zum Zitat Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts: The University of California at San Francisco experience. Ann Surg. 1994;219:267–74.PubMedPubMedCentralCrossRef Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extrahepatic bile ducts: The University of California at San Francisco experience. Ann Surg. 1994;219:267–74.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Cheng Q, Luo X, Zhang B, et al. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol. 2007;33:202–7.PubMedCrossRef Cheng Q, Luo X, Zhang B, et al. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol. 2007;33:202–7.PubMedCrossRef
16.
Zurück zum Zitat Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68:178–82.PubMedCrossRef Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68:178–82.PubMedCrossRef
17.
Zurück zum Zitat Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys. 2011;81:e853–9.PubMedCrossRef Kim TH, Han SS, Park SJ, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys. 2011;81:e853–9.PubMedCrossRef
18.
Zurück zum Zitat Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg. 2001;67:839–43; discussion 843–4.PubMed Serafini FM, Sachs D, Bloomston M, et al. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg. 2001;67:839–43; discussion 843–4.PubMed
19.
Zurück zum Zitat Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.PubMedCrossRef Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002;95:1685–95.PubMedCrossRef
20.
Zurück zum Zitat Mohanty S, Bilimoria KY. Comparing national cancer registries: The National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program. J Surg Oncol. 2014;109:629–30.PubMedCrossRef Mohanty S, Bilimoria KY. Comparing national cancer registries: The National Cancer Data Base (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program. J Surg Oncol. 2014;109:629–30.PubMedCrossRef
21.
Zurück zum Zitat Oshiro Y, Sasaki R, Kobayashi A, et al. Prognostic relevance of the lymph node ratio in surgical patients with extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2011;37:60–4.PubMedCrossRef Oshiro Y, Sasaki R, Kobayashi A, et al. Prognostic relevance of the lymph node ratio in surgical patients with extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2011;37:60–4.PubMedCrossRef
Metadaten
Titel
Adjuvant Chemotherapy and Radiation Therapy is Associated with Improved Survival for Patients with Extrahepatic Cholangiocarcinoma
verfasst von
Richard S. Hoehn, MD
Koffi Wima, MS
Audrey E. Ertel, MD
Alexandra Meier, BS
Syed A. Ahmad, MD
Shimul A. Shah, MD, MHCM
Daniel E. Abbott, MD
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe Sonderheft 3/2015
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4599-8

Weitere Artikel der Sonderheft 3/2015

Annals of Surgical Oncology 3/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.